Rossari Biotech Ltd

Rossari Biotech Ltd share price ticked higher by 4.20% to Rs 454.95 after the company's net profit registered a growth of 10.85% to Rs 38.91 crore, while revenue from operations slightly gained 0.05% to Rs 697.56 crore in Q3FY26 over Q2FY26. The market capitalization of Specialty Chemicals industry group stocks on BSE stood at Rs 5.55 lakh crore, rallying 15.80%. It has softened by 0.67% over last one week and eased lower by 0.46% in last one month while the market capitalization of Rossari Biotech Ltd has improved by 6.72% and 11.17% in the same period respectively. Profit before tax (PBT) of Rossari Biotech Ltd stood at Rs 49.27 crore in Q3 FY26, slipping 0.81% year-on-year, and rising 3.36% quarter-on-quarter. EBITDA came in at Rs 86 crore, jumping 22.84% YoY and heading higher 11.54% sequentially. Total expenses eased by 0.24% to Rs 640.68 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 475.64 crore, easing 7.59% YoY, while employee benefits expense was at Rs 43.62 crore, dipping slightly 0.95% YoY. For the TTM ended FY26, revenue from operations rose 15.19% to Rs 2396.37 crore, while net profit saw a marginal increase of 9.41% to Rs 149.21 crore, compared to previous TTM. EBITDA surged by 27212% to Rs 263.52 crore, and PBT saw a minor gain of 9.36% to Rs 202.52 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 65.07 crore in FY26, as against Rs 137.44 crore in FY25. Rossari Biotech Ltd tumbled by 32.40% in last one year, underperforming the benchmark BSE Sensex which has reduced by 10.47% during the same period.

Rossari Biotech Ltd share price gained 4.20% to Rs 454.95 after the company's net profit rose by 10.85% to Rs 38.91 crore, while revenue from operations slightly gained 0.05% to Rs 697.56 crore in Q3FY26 over Q2FY26. The market capitalization of Specialty Chemicals industry group stocks on BSE stood at Rs 5.43 lakh crore, expanding by 15.80%. It has inched up 0.30% over last one week and moved up slightly by 1.87% in last one month while the market capitalization of Rossari Biotech Ltd has increased 11.10% and 14.27% in the same period respectively. Profit before tax (PBT) of Rossari Biotech Ltd stood at Rs 49.27 crore in Q3 FY26, declining 0.81% year-on-year, and rising 3.36% quarter-on-quarter. EBITDA came in at Rs 86 crore, jumping 22.84% YoY and advancing by 11.54% sequentially. Total expenses slightly declined by 0.24% to Rs 640.68 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 475.64 crore, slightly declining by 7.59% YoY, while employee benefits expense was at Rs 43.62 crore, softening 0.95% YoY. For the TTM ended FY26, revenue from operations improved 15.19% to Rs 2396.37 crore, while net profit saw a marginal increase of 9.41% to Rs 149.21 crore, compared to previous TTM. EBITDA surged by 27212% to Rs 263.52 crore, and PBT saw a minor gain of 9.36% to Rs 202.52 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 65.07 crore in FY26, as against Rs 137.44 crore in FY25. Rossari Biotech Ltd plunged by 32.40% in last one year, underperforming the benchmark BSE Sensex which has declined by 10.47% during the same period.

On the expenditure front, COGS added up to Rs 490.8 crore (up 32.2% YoY), employee benefits expenses amounted to Rs 44.1 crore (up 17.6% YoY) and other expenses aggregated to Rs 81.7 crore (up 21.9% YoY) in the June 2026 quarter. While EBITDA improved by 19% YoY to Rs 80.6 crore, EBITDA margin contracted by 90 basis points YoY to 11.6% in Q1 FY27. Profit before tax in Q1 FY27 stood at Rs 47.7 crore, up by 3.5% from Rs 46.1 crore in Q1 FY26. Edward Menezes, promoter & executive chairman, and Sunil Chari, promoter & managing director, said: 'We commenced FY27 on a strong note, delivering robust consolidated revenue growth of 28% YoY. The performance was driven by healthy momentum in the domestic business and the continued expansion of our international presence. Our HPPC, TSC and AHN businesses delivered YoY growth of 28%, 28% and 27%, respectively, reflecting healthy momentum across the portfolio. Performance was supported by deeper market penetration, expansion into new applications and a higher contribution from differentiated, value-added specialty solutions across end-user industries. Our international business continued to make steady progress, supported by higher wallet share with global partners and growing acceptance of our specialty solutions across key overseas markets. During the quarter, we further strengthened our regional presence with the establishment of a greenfield blending facility in Thailand, designed to serve Southeast Asia. The facility will enhance our ability to offer customised formulations, respond swiftly to local market requirements and improve supply-chain efficiency. Over the past few years, we have made focused investments in developing new capabilities, innovation and product development. Capacity utilisation across these investments has been improving steadily, and our priority is now to drive optimal utilisation, strengthen the product portfolio and enhance operational efficiencies.' Rossari Biotech is a speciality-chemicals manufacturer providing intelligent and sustainable solutions for customers across industries. The company offers tailor-made solutions for home, personal care and performance chemicals (HPPC), textile speciality chemicals (TSC) and animal health and nutrition (AHN). The scrip slipped 1.85% to currently trade at Rs 520.90 on the BSE. Powered by Capital Market - Live

Net profit of Rossari Biotech rose 4.46% to Rs 35.10 crore in the quarter ended June 2026 as against Rs 33.60 crore during the previous quarter ended June 2025. Sales rose 28.23% to Rs 697.20 crore in the quarter ended June 2026 as against Rs 543.72 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales697.20543.72 28 OPM %11.5612.48 - PBDT73.2963.85 15 PBT47.6746.10 3 NP35.1033.60 4 Powered by Capital Market - Live

Rossari Biotech will hold a meeting of the Board of Directors of the Company on 18 July 2026.

Rossari Biotech announced that the Annual General Meeting(AGM) of the company will be held on 20 July 2026.

Rossari Biotech has fixed 10 July 2026 as record date for payment of dividend for FY 2026.

Rossari Biotech announced that the Board of Directors of the Company at its meeting held on 27 April 2026, inter alia, have recommended the final dividend of Rs 0.5 per equity Share (i.e. 25%) , subject to the approval of the shareholders.

Net profit of Rossari Biotech rose 33.48% to Rs 45.97 crore in the quarter ended March 2026 as against Rs 34.44 crore during the previous quarter ended March 2025. Sales rose 18.17% to Rs 684.86 crore in the quarter ended March 2026 as against Rs 579.56 crore during the previous quarter ended March 2025. For the full year,net profit rose 9.41% to Rs 149.21 crore in the year ended March 2026 as against Rs 136.38 crore during the previous year ended March 2025. Sales rose 15.19% to Rs 2396.37 crore in the year ended March 2026 as against Rs 2080.29 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales684.86579.56 18 2396.372080.29 15 OPM %11.2811.99 -11.9312.74 - PBDT87.7765.93 33 281.64252.26 12 PBT64.2447.71 35 202.52185.19 9 NP45.9734.44 33 149.21136.38 9 Powered by Capital Market - Live

Rossari Biotech has allotted 8,250 equity shares under ESOP on 27 April 2026. With this allotment, the paid up equity share capital has increased to Rs. 11,07,83,232 consisting of 55391616 equity shares of Rs. 2/- each.